Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Johnson & Johnson Surgical Vision, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Johnson & Johnson Surgical Vision, Inc.

Regulatory records
32
Linked recall entries
1
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 32 FDA records to the applicant name Johnson & Johnson Surgical Vision, Inc.. It includes 4 original PMA approvals. 7 entries are PMA supplements. 21 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Jan 14, 1983 to Oct 30, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code HQL appears in 18 of the 32 linked filings. The collection spans 4 FDA product codes and 4 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P980040, with 13 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 7 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 31 Technology Dr., Suite 200, Irvine, CA, 92618. Recorded on P810031/S083, decision dated Oct 30, 2026.

Changes described in PMA records

P810031/S083: Healon EndoCoat PRO Sodium Hyaluronate Ophthalmic Viscoelastic Device (OVD); Healon Duet PRO II Dual Pack Sodium Hya

FDA records show supplement P810031/S083, tied to PMA P810031, was approved on 2026-10-30 for a design change. The supplied statement names the change as a new cannula design for the Healon EndoCoat PRO Sodium Hyaluronate Ophthalmic Viscoelastic Device (OVD).

The supplement scope is limited to use with that OVD in the individual pack and the Healon Duet PRO II Dual Pack. The source does not describe the cannula’s design details, any new indication, or any safety or effectiveness findings; it is a change/design supplement, not a new PMA for the whole system.

FDA approval-order wording

approval for a new cannula design for use with the Healon EndoCoat PRO Sodium Hyaluronate Ophthalmic Viscoelastic Device (OVD) in both the individual pack and the Healon Duet PRO II Dual Pack

Oct 30, 2026 · Real-Time Process

P980040/S186: SENSAR 3-Piece Monofocal IOL, SENSAR 1-piece IOL, TECNIS Multi-focal 1-pc, TECNIS 1-PC OptiBlue IOL, TECNIS OptiBlue 1-P

The record covers PMA P980040, supplement S186, with a 30-day notice reason listed as a process change affecting manufacturer, sterilizer, packager, or supplier. The stated change is moving microbiology testing from an external contractor to an in-house laboratory supporting product manufacturing at the AMO Puerto Rico site. The listed devices are the SENSAR 3-Piece Monofocal IOL, SENSAR 1-piece IOL, TECNIS Multi-focal 1-pc, TECNIS 1-PC OptiBlue IOL and TECNIS OptiBlue 1-P, product code HQL, applicant Johnson & Johnson Surgical Vision, Inc.

S186 is a supplement to the existing PMA identified by the database, not a new approval of the whole lens system. The source states the intended purpose of the transfer; it does not report microbiology results, testing validation data or an independent finding of safety or effectiveness. The record also does not specify which lens models the in-house laboratory serves, the tests transferred, or the contractor involved.

The decision field reads OK30, dated 2026-10-19. Beyond that label and the notice reason, the supplied fields do not describe the decision's scope or any conditions.

FDA approval-order wording

the transfer of microbiology testing from an external contractor to an in-house laboratory to support product manufacturing at the AMO Puerto Rico manufacturing site

Oct 19, 2026 · 30-Day Notice

P990080/S067: TECNIS Foldable Acrylic IOL with OptiEdge, Model ZA9003

FDA database record P990080/S067 describes a 30-day notice for the TECNIS Foldable Acrylic IOL with OptiEdge, Model ZA9003. The stated change is the transfer of microbiology testing from an external contractor to an in-house laboratory to support product manufacturing at the AMO Puerto Rico manufacturing site. The applicant is Johnson & Johnson Surgical Vision, Inc., and the supplement type is a process change involving manufacturer, sterilizer, packager, or supplier.

This supplement does not represent a new approval of the intraocular lens system. The record identifies the original PMA number P990080, but the notice concerns only the reported testing location change. The source statement describes the purpose of the change; it does not provide independent proof of safety or clinical effectiveness. Specific details about validation results, test methods, or manufacturing impact are absent from the supplied fields.

FDA approval-order wording

the transfer of microbiology testing from an external contractor to an in-house laboratory to support product manufacturing at the AMO Puerto Rico manufacturing site

Oct 19, 2026 · 30-Day Notice

P080010/S032: TECNIS Multi-focal 3-pc, Model ZMA00

The FDA record for P080010/S032 covers the TECNIS Multi-focal 3-pc, Model ZMA00, a multifocal intraocular lens in the ophthalmic specialty under product code MFK, submitted by Johnson & Johnson Surgical Vision, Inc. The supplement is a 30-Day Notice filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, and the recorded decision is OK30, dated 2026-10-19.

The recorded change is the transfer of microbiology testing from an external contractor to an in-house laboratory supporting product manufacturing at the AMO Puerto Rico manufacturing site. This notice concerns that testing-location change within the existing application; it is not a new approval of the lens itself. The public documentation includes no documents, so the notice's technical content and any FDA review detail beyond the recorded fields remain unknown.

Whether the in-house laboratory's methods, validation data or inspection outcome were assessed is not stated in the available record, and no clinical or legal conclusion about the device should be drawn from this administrative entry.

FDA approval-order wording

the transfer of microbiology testing from an external contractor to an in-house laboratory to support product manufacturing at the AMO Puerto Rico manufacturing site

Oct 19, 2026 · 30-Day Notice

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

RECALL COVERAGE

Recalls linked to this firm

MedtechLedger links 1 FDA enforcement entry through the recorded recalling firm or an exact submission number published in FDA’s recall data. 1 Class II records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.

Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.

Source information

Source updated Nov 11, 2026. Retrieved Nov 20, 2026.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Johnson & Johnson Surgical Vision, Inc.PMA supplementOct 30, 2026FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementOct 19, 2026FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementOct 19, 2026FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementOct 19, 2026FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementJul 28, 2026FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementJul 23, 2026FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementJun 3, 2026FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementJun 3, 2026FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementJun 3, 2026FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementMay 19, 2026FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementMar 11, 2026FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementJan 12, 2026FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementJan 12, 2026FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementJan 12, 2026FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementDec 16, 2025FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementDec 16, 2025FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementOct 28, 2025FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementOct 24, 2025FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementSep 11, 2025FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementSep 10, 2025FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementSep 10, 2025FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementSep 10, 2025FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementSep 2, 2025FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementSep 2, 2025FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementSep 2, 2025FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementJul 22, 2025FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementJul 22, 2025FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementJul 22, 2025FDA
Johnson & Johnson Surgical Vision, Inc.PMA approvalJan 16, 2009FDA
Johnson & Johnson Surgical Vision, Inc.PMA approvalApr 5, 2001FDA
Johnson & Johnson Surgical Vision, Inc.PMA approvalFeb 3, 2000FDA
Johnson & Johnson Surgical Vision, Inc.PMA approvalJan 14, 1983FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 20, 2026.